8-K: KALA BIO Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO reports financial results for Q4 and full year 2024, highlights progress on KPI-012 clinical trial, and announces $10.75 million in private placement financing.

Summary

• KALA BIO reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focused on developing KPI-012 for persistent corneal epithelial defect (PCED).
• KALA BIO raised $10.75 million through a private placement.
• As of December 31, 2024, KALA BIO had $51.2 million in cash resources, expected to fund operations into the first quarter of 2026.
• The Phase 2b CHASE trial of KPI-012 has randomized 87 patients to date and is continuing enrollment into 2Q25.
• Topline data from the CHASE trial is expected in 3Q25.
• The company is also exploring KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD).
• KALA BIO's preclinical program, KPI-014, is evaluating the utility of its MSC-S platform for inherited retinal degenerative diseases.
• For the quarter ended December 31, 2024, general and administrative (G&A) expenses were $4.2 million, compared to $4.6 million for the same period in 2023.
• For the quarter ended December 31, 2024, research and development (R&D) expenses were $5.3 million, compared to $4.7 million for the same period in 2023.
• For the quarter ended December 31, 2024, net loss was $8.2 million, or $1.74 per share, compared to a net loss of $8.6 million, or $3.18 per share, for the same period in 2023.
• For the full year ended December 31, 2024, G&A expenses were $18.3 million, compared to $20.6 million for the same period in 2023.
• For the full year ended December 31, 2024, R&D expenses were $22.1 million, compared to $18.6 million for the same period in 2023.
• For the full year ended December 31, 2024, net loss was $38.5 million, or $10.15 per share, compared to a net loss of $42.2 million, or $17.35 per share, for the same period in 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company has secured funding and is progressing with its clinical trials, but there are also ongoing losses and a delay in the topline data readout.

Positives

• KALA BIO secured $10.75 million in private placement financing, strengthening its balance sheet.
• The company's cash runway extends into the first quarter of 2026.
• Enrollment in the Phase 2b CHASE trial has seen an uptick, with 87 patients randomized.
• KALA BIO is expanding its clinical trial sites to Latin America.
• KALA BIO received $2.5 million under the CIRM award in December 2024.

Negatives

• The topline data readout for the CHASE trial has been delayed to the third quarter of 2025 due to enrollment adjustments.
• KALA BIO reported a net loss of $38.5 million for the full year ended December 31, 2024.
• The company prepaid $5.0 million in principal and fees on its debt facility.

Risks

• The success of the CHASE trial is crucial, and any negative results could significantly impact the company's prospects.
• Regulatory approval of KPI-012 is not guaranteed, and the FDA may require additional studies.
• KALA BIO may need to raise additional capital in the future, which could dilute existing shareholders.
• The company faces competition from other companies developing treatments for ocular diseases.
• Uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials could impact results.

Future Outlook

KALA BIO anticipates that its cash resources as of December 31, 2024 will enable it to fund operations into the first quarter of 2026 and plans to report topline clinical data in the third quarter of 2025.

Management Comments

• Todd Bazemore, interim Chief Executive Officer of KALA BIO, stated that the company is well-positioned to execute its clinical and strategic priorities, with KPI-012 at the center of its efforts.
• Mr. Bazemore expressed encouragement regarding the potential of KPI-012 to address all underlying etiologies of PCED and significantly improve patient outcomes.

Industry Context

KALA BIO is operating in the biopharmaceutical industry, specifically focusing on rare and severe diseases of the eye, and is competing with other companies developing treatments for similar conditions. The company's focus on its MSC-S platform and KPI-012 for PCED positions it within the orphan drug market, which often offers incentives and market exclusivity.

Comparison to Industry Standards

• KALA BIO's focus on orphan ocular diseases aligns with companies like REGENXBIO and Adverum Biotechnologies, which are developing gene therapies for retinal diseases.
• The $10.75 million private placement is relatively small compared to larger financings by companies like Iveric Bio, which raised hundreds of millions for its geographic atrophy program.
• The cash runway into Q1 2026 is a positive sign, but it's shorter than some peers who have cash to last for several years based on current burn rates.
• The company's R&D expenses of $22.1 million for the full year 2024 are in line with other clinical-stage biopharmaceutical companies of similar size and focus.

Stakeholder Impact

• Shareholders: The financial results and clinical trial progress will impact shareholder value.
• Employees: The company's financial stability and clinical progress affect job security and opportunities.
• Patients: The development of KPI-012 could provide a new treatment option for PCED and other ocular diseases.
• Investors: The company's ability to secure funding and achieve clinical milestones will influence investor confidence.

Next Steps

• Continue enrollment in the CHASE Phase 2b clinical trial.
• Report topline data from the CHASE trial in the third quarter of 2025.
• Advance the MSC-S platform technology for the treatment of rare and severe ocular diseases.
• Explore the potential of KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD).
• Continue preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases.

Key Dates

Keywords

KALA BIO, KPI-012, PCED, CHASE trial, MSC-S platform, Clinical trial, Financial results, Private placement, Ocular diseases, Biopharmaceutical